Novartis, MSN End Trademark Appeal Over ‘Novadoz’ Entresto Copy

Sept. 30, 2025, 11:12 PM UTC

MSN Laboratories Pvt Ltd. and Novartis AG jointly requested dismissal of a trademark dispute over a generic version of the blockbuster heart-disease drug, Entresto.

The dismissal, which was approved the same day, ends MSN’s appeal of a preliminary injunction blocking its “Novadoz”-branded copy of Novartis’ Entresto.

Novartis’ appeal of its loss in a separate patent infringement suit against the generics maker remains before the US Court of Appeals for the Federal Circuit. Both appellate courts rejected Novartis’s request to block the launch of MSN’s copy during the appeals.

Novartis sued MSN in January, accusing the company of trademark infringement because ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.